Nad+ Activates Immune Responses Against Lethal Infections

Nicotinamide adenine dinucleotide (NAD+), a natural occurring cell molecule when administered into the body activates the cellular and molecular pathway that regulates the CD4+ T cells, finds a research team at Brigham and Women's Hospital (BWH). The NAD+ shuts off the capacity of the dendrite and macrophage cells which are responsible for fate of CD4+ T cells and regulate them through the mast cells. This helps in treating disease that rise due to the alterations occurring in CD4+T cells. The findings of the study are published in the Journal of Allergy and Clinical Immunology.

"This is a novel cellular and molecular pathway that is distinct from the two major pathways that were previously known. Since it is distinct and since it has the ability to regulate the immune system systemically, we can use it as an alternative to bypass the current pathways," said Abdallah ElKhal, PhD, BWH Department of Surgery, senior study author.

‘Nicotinamide adenine dinucleotide (NAD+) activates the molecular pathway that regulates the CD4+T cell response which protects the body against infections and allergies.’

CD4+ T helper cells and dendritic cells play a central role in immunity. Alterations or aberrant dendritic cells and T cell responses can lead to many health conditions including autoimmune diseases, infections, allergy, primary immunodeficiencies and cancer.

As of today, two major pathways have been described to regulate CD4+ T cell response. The first pathway was described by Peter C. Doherty and Rolf M. Zinkernagel (1996 Nobel prize winners) showing the requirement of MHC-TCR signaling machinery. More recently, a second mechanism involving the Pathogen or Damage Associated Molecular Patterns (PAMPs or DAMPs) was unraveled by Bruce A. Beutler and Jules A. Hoffmann (2011 Nobel Prize winners). Of importance, both pathways require antigen presenting cells (APCs) in particular dendritic cells (DCs) or macrophages (M�). Elkhal's novel pathway is distinct from the two previous ones and may offer a path forward for novel therapeutic approaches.

For the current study, BWH researchers performed pre-clinical trials using an experimental infection model. They showed that mast cell-mediated CD4+ T cell response protects against lethal doses of infection (Listeria monocytogenes). Mice treated with NAD+ had a dramatically increased survival rate when compared to the non-treated group.

"Collectively, our study unravels a novel cellular and molecular pathway that regulates innate and adaptive immunity via MCs, exclusively, and underscores the therapeutic potential of NAD+ in the context of a myriad of diseases including autoimmune diseases, hemophilia, primary immunodeficiencies and antimicrobial resistance," said Elkhal.



Source: Eurekalert